144 related articles for article (PubMed ID: 27443263)
1. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
Cruickshank MN; Ford J; Cheung LC; Heng J; Singh S; Wells J; Failes TW; Arndt GM; Smithers N; Prinjha RK; Anderson D; Carter KW; Gout AM; Lassmann T; O'Reilly J; Cole CH; Kotecha RS; Kees UR
Leukemia; 2017 Jan; 31(1):40-50. PubMed ID: 27443263
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
3. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
5. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
6. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
7. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
8. Trametinib inhibits
Kerstjens M; Pinhancos SS; Castro PG; Schneider P; Wander P; Pieters R; Stam RW
Haematologica; 2018 Apr; 103(4):e147-e150. PubMed ID: 29419436
[No Abstract] [Full Text] [Related]
9. Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.
Candelli T; Schneider P; Garrido Castro P; Jones LA; Bodewes E; Rockx-Brouwer D; Pieters R; Holstege FCP; Margaritis T; Stam RW
Leukemia; 2022 Jan; 36(1):58-67. PubMed ID: 34304246
[TBL] [Abstract][Full Text] [Related]
10. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
11. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
12. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.
Bardini M; Woll PS; Corral L; Luc S; Wittmann L; Ma Z; Lo Nigro L; Basso G; Biondi A; Cazzaniga G; Jacobsen SE
Leukemia; 2015 Jan; 29(1):38-50. PubMed ID: 24798483
[TBL] [Abstract][Full Text] [Related]
13. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
Stumpel DJ; Schneider P; Seslija L; Osaki H; Williams O; Pieters R; Stam RW
Leukemia; 2012 Apr; 26(4):682-92. PubMed ID: 22015773
[TBL] [Abstract][Full Text] [Related]
14. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
Spijkers-Hagelstein JA; Pinhanços SS; Schneider P; Pieters R; Stam RW
Leukemia; 2014 Apr; 28(4):761-9. PubMed ID: 23958920
[TBL] [Abstract][Full Text] [Related]
15. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia.
Chowdhury T; Brady HJ
Blood Cells Mol Dis; 2008; 40(2):192-9. PubMed ID: 17905612
[TBL] [Abstract][Full Text] [Related]
16. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.
Somers K; Chudakova DA; Middlemiss SM; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ
Oncotarget; 2016 Jul; 7(29):46067-46087. PubMed ID: 27317766
[TBL] [Abstract][Full Text] [Related]
17. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Wander P; Cheung LC; Pinhanҫos SS; Jones L; Kerstjens M; Arentsen-Peters STCJM; Singh S; Chua GA; Castro PG; Schneider P; Dolman MEM; Koopmans B; Molenaar JJ; Pieters R; Zwaan CM; Kotecha RS; Stam RW
Leukemia; 2020 Nov; 34(11):2898-2902. PubMed ID: 32488115
[No Abstract] [Full Text] [Related]
19. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4
Bardini M; Trentin L; Rizzo F; Vieri M; Savino AM; Garrido Castro P; Fazio G; Van Roon EHJ; Kerstjens M; Smithers N; Prinjha RK; Te Kronnie G; Basso G; Stam RW; Pieters R; Biondi A; Cazzaniga G
Mol Cancer Ther; 2018 Aug; 17(8):1705-1716. PubMed ID: 29748211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
